Alpha Tau Medical Announces First Quarter 2023 Financial Results and Provides Corporate Update
– Opened U.S. multicenter pivotal trial in recurrent cutaneous skin cancer, which began enrolling patients in March –
Related news for (DRTS)
- Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
- Alpha Tau Medical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
- Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Alpha Tau to Present at the 42nd Annual J.P. Morgan Healthcare Conference
